Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Trial of Daratumumab and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia Post-Allogeneic Hematopoietic Stem Cell Transplant

NCT03537599 is registered in ClinicalTrials.gov with Sumithira Vasu as lead sponsor.

NCT NCT03537599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03537599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Trial of Daratumumab and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia Post-Allogeneic Hematopoietic Stem Cell Transplant
Lead sponsor
Sumithira Vasu
Phase
Phase 1/2
Overall status
Terminated
Start date
January 10, 2020
Completion date
February 3, 2022
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

minimal residual disease, recurrent acute myeloid leukemia with myelodysplasia-related changes, recurrent adult acute myeloid leukemia, recurrent childhood acute myeloid leukemia